A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06018337 |
|
Recruitment Status :
Recruiting
First Posted : August 30, 2023
Last Update Posted : February 8, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Metastatic Breast Cancer | Drug: DB-1303/BNT323 Drug: Capecitabine Drug: Paclitaxel Drug: Nab-paclitaxel | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 532 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) |
| Actual Study Start Date : | January 18, 2024 |
| Estimated Primary Completion Date : | December 2025 |
| Estimated Study Completion Date : | May 2028 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: DB-1303/BNT323
Enrolled Subjects will be randomized to receive a 8 mg/kg IV dose of DB-1303/BNT323 on Day 1 of each cycle Q3W
|
Drug: DB-1303/BNT323
IV |
|
Active Comparator: investigator's choice single agent chemotherapy
Enrolled Subjects will be randomized to receive investigator's choice single agent chemotherapy (capecitabine:1000 or 1250 mg/m2, Oral, Twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles; paclitaxel：80 mg/m2， IV, Every week (QW) in 3-week cycles; or nab-paclitaxel: 100 mg/m2, IV, Every week (QW) for 3 weeks followed by a one-week rest period in 4-week cycles) until RECIST 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
|
Drug: Capecitabine
Oral Drug: Paclitaxel IV Drug: Nab-paclitaxel IV |
- Progression-free survival (PFS) in the HR+, HER2-low population [ Time Frame: Up to approximately 51 months ]PFS by BICR according to RECIST 1.1 in the HR+, HER2-low population
- Overall survival (OS) in the HR+, HER2-low population [ Time Frame: Up to approximately 51 months ]OS in the HR+, HER2-low population
- Objective response rate (ORR) in the HR+, HER2-low population [ Time Frame: Up to approximately 51 months ]ORR by BICR and Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population
- PFS by Investigator assessment [ Time Frame: Up to approximately 51 months ]PFS by Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population
- Duration of response (DoR) in the HR+, HER2-low population [ Time Frame: Up to approximately 51 months ]DoR by BICR and Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population
- Treatment-emergent adverse events (TEAEs) [ Time Frame: from the time of the subject signing the informed consent form (ICF) until the follow-up period is completed (35 days after the last doseof study treatment ]TEAEs per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
- Serious adverse events (SAEs) [ Time Frame: from the time of the subject signing the ICF until the follow-up period is completed (35 days after the last doseof study treatment ]SAEs per NCI CTCAE v5.0
- Patient reported outcomes (PROs): European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) - C30 [ Time Frame: Up to approximately 51 months ]Change from baseline in the functioning/symptom/global quality of life (QoL) subscales of EORTC QLQ-C30. Scale scores range from 0-100. For functioning and global QoL scales, higher scores indicate better functioning or global health status. For symptom scales, higher scores indicate greater symptom burden.
- Patient reported outcomes (PROs): EORTC QLQ-BR45 [ Time Frame: Up to approximately 51 months ]Change from baseline in the functioning/symptom subscales of EORTC QLQ-BR45. Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.
- Patient reported outcomes (PROs): European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) [ Time Frame: Up to approximately 51 months ]Change from baseline in EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. VAS score range from 0-100, higher scores indicate better health status.
- European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) [ Time Frame: Up to approximately 51 months ]EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. The change from baseline value will be reported.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).
- Pathologically documented breast cancer that:
1) Is advanced or metastatic 2) Has HER2-low expression (IHC 1+ or IHC 2+/ISH-) as determined by the central laboratory result.
3) Was never previously reported as HER2-positive (IHC 3+ or ISH+) as per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
4) Is documented as HR+ (either estrogen receptor [ER] and/or progesterone receptor [PgR] positive [ER or PgR ≥1%]) per ASCO/CAP guidelines (Allison et al 2020).
3. Must have an adequate tumor tissue sample available for assessment of HER2 by central laboratory, preferably in formalin fixation and paraffin embedding (FFPE) blocks based on a mandatory FFPE tumor sample obtained at the time of metastatic disease or later;
4. Eastern Cooperative Oncology Group performance status of 0 or 1.
5. Must have had either:
- Disease progression on endocrine therapy + CDK4/6 inhibitor within 6 months of starting first line treatment for metastatic disease and considered appropriate for chemotherapy as the next treatment by the investigator, OR
- Disease progression on at least 2 previous lines of ET with or without a targeted therapy (such as CDK4/6, mammalian target of rapamycin [mTOR] or phosphoinositide 3-kinase [PI3-K] inhibitors) administered for the treatment of metastatic disease.
6. No prior chemotherapy for advanced or metastatic breast cancer. Subjects who have received chemotherapy in the neo-adjuvant or adjuvant setting are eligible, as long as they have had a disease-free interval (defined as completion of systemic chemotherapy to diagnosis of advanced or metastatic disease) of >12 months.
7. Life expectancy ≥12 weeks at screening.
8. Subjects must have at least one measurable lesion as defined per RECIST v1.1 or have non-measurable, bone-only disease that can be assessed by computer tomography (CT) or Magnetic Resonance Imaging (MRI) or X-Ray. Lytic or mixed lytic bone lesions that can be assessed by CT or MRI or X-Ray in the absence of measurable disease as defined above is acceptable; subjects with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible.
9. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 7 months after the last dose of study treatment.
10. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening and throughout the duration of the study treatment and the washout period
Exclusion Criteria:
- Ineligible for all options in the investigator's choice chemotherapy arm.
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events or compromise the ability of the subject to give written informed consent.
- Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the randomization.
- Uncontrolled or significant cardiovascular disease
- Has as a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Subjects with prior use of immunosuppressive medication within 14 days prior to first study dose, except for intranasal and inhaled corticosteroids or systemic corticosteroids at doses less than 10 mg/day of prednisone or equivalent.
- Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline.
- Previous treatment with anti-HER2 therapy.
- Prior treatment with antibody-drug conjugate that comprised an exatecan derivative that is a topoisomerase I inhibitor.
- Prior randomization or treatment in a previous DB-1303/BNT323 study regardless of treatment assignment.
- Has substance abuse or any other medical conditions such as psychological conditions, that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06018337
| Contact: Helen Liu | 86-21-26018730 | helen.liu@dualitybiologics.com | |
| Contact: Michael Sun | michael.sun@dualitybiologics.com |
| United States, Kentucky | |
| Alliance For Multispeciality Research, LLC | Recruiting |
| Lexington, Kentucky, United States, 40593 | |
| Contact: Singh Jaswinder, M.D. | |
| United States, Texas | |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Not yet recruiting |
| Dallas, Texas, United States, 75246 | |
| Contact: Joyce O Shaughnessy | |
| Australia, Queensland | |
| Master Hospital Brisbane | Recruiting |
| South Brisbane, Queensland, Australia | |
| Contact: Catherine Shannon, M.D. | |
| China, Shanghai | |
| Fudan University Shanghai Cancer Center | Recruiting |
| Shanghai, Shanghai, China | |
| Contact: Zhimin Shao, M.D. | |
| Study Director: | Raymond Zhao | DualityBio Inc. |
| Responsible Party: | DualityBio Inc. |
| ClinicalTrials.gov Identifier: | NCT06018337 |
| Other Study ID Numbers: |
DB-1303-O-3002 CTR20233708 ( Other Identifier: CENTER FOR DRUG EVALUATION, NMPA ) |
| First Posted: | August 30, 2023 Key Record Dates |
| Last Update Posted: | February 8, 2024 |
| Last Verified: | February 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
HER2-low IHC 2+ BC Breast Cancer |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Albumin-Bound Paclitaxel Capecitabine |
Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites |